Ot­su­ka calls off multi­bil­lion-dol­lar, CKD li­cens­ing deal with Ake­bia in af­ter­math of CRL

Back in 2016, Ot­su­ka and Ake­bia signed the first li­cens­ing and co-de­vel­op­ment agree­ment for vadadu­s­tat, a drug can­di­date for re­nal ane­mia re­lat­ed to chron­ic kid­ney …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER